Strategic Advisors LLC lowered its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 19.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,111 shares of the medical research company’s stock after selling 729 shares during the period. Strategic Advisors LLC’s holdings in Amgen were worth $541,000 as of its most recent filing with the SEC.
Several other institutional investors have also bought and sold shares of the company. Toronto Dominion Bank grew its position in Amgen by 11.0% during the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after acquiring an additional 27,726 shares during the last quarter. Welch Group LLC bought a new stake in Amgen during the 2nd quarter worth $639,000. DekaBank Deutsche Girozentrale grew its position in Amgen by 2.8% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 883,579 shares of the medical research company’s stock worth $152,927,000 after acquiring an additional 24,219 shares during the last quarter. Pacer Advisors Inc. grew its position in Amgen by 10.3% during the 2nd quarter. Pacer Advisors Inc. now owns 25,378 shares of the medical research company’s stock worth $4,371,000 after acquiring an additional 2,362 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in Amgen by 16.5% during the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after acquiring an additional 104,871 shares during the last quarter. 78.03% of the stock is owned by institutional investors.
In related news, EVP Sean E. Harper sold 1,525 shares of the company’s stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 4,575 shares of company stock worth $818,361. 0.19% of the stock is owned by company insiders.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. During the same period last year, the company posted $2.89 earnings per share. The firm’s quarterly revenue was down 2.7% compared to the same quarter last year. analysts anticipate that Amgen, Inc. will post 13.21 earnings per share for the current year.
Amgen declared that its board has authorized a share repurchase program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Investors of record on Thursday, February 15th will be paid a dividend of $1.32 per share. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. The ex-dividend date is Wednesday, February 14th. Amgen’s dividend payout ratio is 205.45%.
A number of brokerages recently weighed in on AMGN. Atlantic Securities lowered Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price objective on the stock. in a research report on Monday, February 5th. Piper Jaffray Companies reduced their price objective on Amgen from $194.00 to $190.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Mizuho boosted their price objective on Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, February 12th. Oppenheimer set a $205.00 price objective on Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, BMO Capital Markets boosted their price objective on Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research report on Friday, February 2nd. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $191.84.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://weekherald.com/2018/02/20/amgen-inc-amgn-shares-sold-by-strategic-advisors-llc.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.